Keywords: strong, ph, i/ii, data, keryx, perifosine, usa-based
Strong Ph I/II data for Keryx' perifosine
Article | 09 July 2007
USA-based Keryx Biopharmaceuticals presented data at the 11th International Myeloma workshop, held in Kos, Greece, demonstrating clinical activity of KRX-0401 ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
